Skip to main content

Table 5 Comparison of OS and PFS between the two groups

From: Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study

 

Gruop

Median(months)

95% Confidence Interval

Log Rank (Mantel-Cox) (p-value)

Lower Bound

Upper Bound

PFS

TACE + Sunitinib group

15.6

14.9

17.1

< 0.001

Sunitinib group

10.9

8.9

11.1

OS

TACE + Sunitinib group

35.0

32.7

37.4

< 0.001

Sunitinib group

25.7

23.6

27.8